TRIO 2016.

Methods	Study design: RCT Study duration: August 2005 to July 2010 Follow‐up period: 24 months
Participants	Countries: Canada and Hong Kong Setting: multicentre Incident adults CAPD or APD patients Number: treatment group (51); control group (50) Mean age ± SD (years): treatment group ( 59.9 ± 11); control group (59.0 ± 11) Sec (M/F): treatment group (29/22); control group (31/19) Exclusion criteria: unlikely to continue PD for at least 6 months
Interventions	Treatment group Neutral pH, low GDP PD solution (Gambrosol Trio solution) Control group Conventional PD solution (Dianeal solution)
Outcomes	RRF Urine output 4‐hour dialysate:plasma creatinine Peritoneal small solute clearance Peritoneal UF peritonitis rate
Notes	"The Trio Trial was partially funded by an unrestricted grant from Gambro Lundia AB, Lund, Sweden. TS, GW, MT, DO, and PT conceived, designed, and supervised the Trio Trial. TS, SM, AS, and MA conducted the statistical analysis"
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Standard computerized algorithm
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Open‐label, unlikely to have major impact on outcomes of study
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Unlikely to effect the outcomes of study
Incomplete outcome data (attrition bias) All outcomes	High risk	33% dropout rate
Selective reporting (reporting bias)	Low risk	All outcomes of study were reported
Other bias	Unclear risk	Insufficient information to permit judgement